[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cannabis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cannabis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,76,101,128,154,181,207,243,271,291,319,344,368,392,421,442,459,483,502,517,548,576],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100054313","transcranial-magnetic-brain-stimulation-to-reduce-cannabis-use-in-heavy-cannabis-users-100054313",false,"NCT05401929","Transcranial Magnetic Brain Stimulation to Reduce Cannabis Use in Heavy Cannabis Users","Imaging the Effects of Intermittent Thetaburst Stimulation on Cannabis Self-Administration in Heavy Cannabis Users","iCURE","Inclusion Criteria:\n\n* Males\u002Fnon-pregnant females, 18-65 years old\n* Current cannabis user\n* Able to perform all study procedures\n\nExclusion Criteria:\n\n* Regular use of other illicit drugs\n* If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process reveal any significant illness that the study physician deems contraindicated for study participation",true,"ALL","18 Years","65 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"NA","The growing legalization of cannabis across the U.S. is associated with increases in cannabis use, and accordingly, an increase in the number of individuals with cannabis use problems, including cannabis use disorder (CUD). While there are several medications being investigated as treatment options for CUD, none have been FDA-approved, and there is limited efficacy of traditional behavioral therapy approaches for this population. Consequently, there is a pressing need for the development of new treatments, including approaches that specifically target the brain areas associated with problematic cannabis use behaviors. Elevated attention to drug cues is one of the primary causes of relapse in heavy cannabis users. Preliminary data suggests that repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, may be a novel brain-based tool to decrease heightened attention to drug cues in people with CUD. Building on prior data, the primary goal of this study is to evaluate the feasibility and effectiveness of TMS as a tool to decrease attention to drug cues and reduce cannabis use.\n\nIn this study, fifty (50) treatment-seeking, near-daily cannabis users will be recruited to receive either active or sham (placebo) repetitive TMS (rTMS). Participants will complete a total of 25 treatment sessions, delivered as five sessions per day across five days, with sessions flexibly scheduled over a two-week period. Measures of cannabis use and brain activity will be collected before and after treatment using real-time self-report assessments and functional magnetic resonance imaging (fMRI), respectively. Specifically, cannabis use will be assessed in participants' everyday environments using brief text-message surveys during a two-week baseline period, the two-week treatment period, and a four-week follow-up period.\n\nThe study aims to determine whether active rTMS reduces brain activity in response to cannabis cues, decreases automatic attention to cannabis cues, and leads to meaningful reductions in cannabis use compared to sham treatment.",[29],"Cannabis",[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62],"cannabis","transcranial magnetic stimulation","repetitive transcranial magnetic stimulation","intermittent theta burst stimulation","functional magnetic resonance imaging","functional neuroimaging","functional brain imaging","marijuana","cannabis smoking","marijuana smoking","recreational marijuana use","stroop task","attentional bias","drug cue reactivity","intervention","treatment","double blind","sham","sham controlled","ecological momentary assessment","randomized controlled clinical trials","randomized clinical trials","neuronavigation","personalized cortical targeting","biomarker development","brain mapping","neuroendophenotypes","neurobiomarkers","accelerated","functional connectivity","network","fmri","RECRUITING","2026-07-10",{"date":66,"type":67},"2026-07-13","ACTUAL",{"date":69,"type":67},"2022-06-01",{"date":71,"type":23},"2029-07",{"name":73,"class":74},"Duke University","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":75},"100054054","developing-and-strengthening-cannabis-warnings-warning-message-testing-100054054","NCT07699198","Developing and Strengthening Cannabis Warnings: Warning Message Testing","Inclusion Criteria:\n\n* Age 18 years of age and older\n* Live in the United States\n\nExclusion Criteria:\n\n* Age less than 18 years of age\n* Does not live in the United States",{"count":83,"type":23},1500,[26],"The purpose of this activity is to identify promising cannabis warning messages from different themes. Participants will be adults who live in the United States, including both people who use cannabis and those who do not use cannabis. In an online within-subjects experiment, participants will be randomly assigned to view 7 cannabis warning messages from different themes developed as part of previous study activities. After viewing each cannabis warning message, participants will rate the message on awareness, clarity, believability, cognitive elaboration, perceived message effectiveness, and reactance. The survey will take 15-20 minutes.",[29,87],"Marijuana Use",[29,87,89,90,91,92],"Product Packaging","Product Labeling","Warnings","Health Communication","NOT_YET_RECRUITING","2026-07-08",{"date":66,"type":67},{"date":66,"type":23},{"date":98,"type":23},"2026-11-30",{"name":100,"class":74},"University of North Carolina, Chapel Hill",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":17,"sex":18,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":75},"100645177","cannabis-observations-on-brain-waves-retrieval-and-attention-experiment-4-100645177","NCT07679581","Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 4","Cannabis and Memory","COBRA 4","1. Must be between the ages of 21 and 40 and provide informed consent;\n2. Must be right-handed (Laterality Quotient \\> 60 on Edinburgh Handedness Inventory - Short Form136);\n3. Heavy users (HU) in Experiments 1, 2, 3, and 4:\n\n   1. Must use cannabis at least 4 days during the month;\n   2. Must be a cannabis user for at least a year;\n4. Non-users (NU) in Experiment 2:\n\n   1. Must not have used cannabis for prior 6 months;\n   2. Must have at least one episode of lifetime cannabis use;\n5. Must self-report not using other illicit recreational drugs (e.g., cocaine, benzodiazepines (non-prescription), opiates (non-prescription), MDMA, sedatives, or methamphetamine) in the past 30 days, during the Pre-Screening;\n6. Must not test positive on a urine toxicology test for drugs of abuse at the Baseline Appointment (TDS);\n7. Must not be using psychotropic medications, however anti-depressant, non-benzodiazepine anti-anxiety, and ADHD medications are ok. ADHD medication users must be willing to abstain from ADHD medication use on appointment days; ADHD medications, even extended-release forms, are short acting and medication\" holidays\" (e.g., on weekends and holidays) are routine in individuals prescribed ADHD medications, without adverse effects.\n8. Must not be a regular nicotine user (≤4 days per week; cigarette, E-cigs, or smokeless);\n9. Must not have used caffeine or nicotine (cigarette, E-cigs, or smokeless) for 4 hours;\n10. Must have a breath alcohol level of 0 at screening (to sign consent form);\n11. Must not be actively seeking or in treatment for any substance use disorder (drug use levels will be carefully monitored via Timeline Follow Back (TLFB) throughout the study to assess any confounding influences of drug or alcohol use;\n12. Female subjects must not be or trying to become pregnant (as indicated by a pregnancy test \\& screening form administered at Baseline);\n13. Must not be in treatment for psychotic disorder or bipolar disorder; or have a history with these disorders;\n14. Must not have any physical characteristics (e.g., thick hair, head size exceeding the limit of the net, dyed hair) or experience any technical difficulties during testing that result in a poor-quality EEG recording.\n15. Participants in Experiment 4 a. Must not have participated in Experiment 3","21 Years","40 Years",{"count":112,"type":23},64,"OBSERVATIONAL","This study investigates the impact of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on recognition memory in healthy, regular cannabis users. Participants complete the same recognition memory task after self-administering one of two different strains of cannabis flower one day and while not intoxicated another day. Event-related potentials (ERPs) are measured via electroencephalogram (EEG) during the recognition memory task. Blood is collected to quantify THC and CBD exposure. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.",[29,116,117],"Memory","Electroencephalography",[29,116,117],"2026-06-29",{"date":121,"type":67},"2026-07-01",{"date":123,"type":67},"2025-12-10",{"date":125,"type":23},"2027-05-31",{"name":127,"class":74},"L. Cinnamon Bidwell",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":18,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":24,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100642032","allergenic-risk-assessment-of-hemp-seed-100642032","NCT07652853","Allergenic Risk Assessment of Hemp Seed","ARCANA-Clinic","Inclusion Criteria:\n\n* Patients aged 2 years or older\n* Belonging to one or more of the target populations:\n\n  i) Individuals with known or suspected cannabis allergy: Allergy or suspected allergy to hemp seed (HS) defined by A suggestive clinical history of HS allergy and Positive skin prick test (SPT) to HS (≥ 6 mm with erythema exceeding the control papule) and\u002For Basophil activation test (BAT) confirming HS allergy diagnosis OR Allergy or suspected allergy to hemp flower (female or male) defined by a suggestive clinical history of hemp allergy and positive SPT to hemp flower (≥ 6 mm with erythema) and\u002For ImmunoCAP IgE to hemp \\> 0.35 KU\u002FL ii) Individuals allergic to tree nuts (hazelnut or walnut): Allergy to walnut defined by a suggestive clinical history of IgE-mediated walnut allergy and positive SPT to walnut (≥ 8 mm) and IgE to Jug r 1, Jug r 2, or Jug r 3 \\> 1 KU\u002FL and\u002For BAT confirming walnut allergy diagnosis OR Allergy to hazelnut defined by a suggestive clinical history of IgE-mediated hazelnut allergy and positive SPT to hazelnut (≥ 8 mm) and IgE to Cor a 9, Cor a 11, Cor a 14, or Cor a 8 \\> 1 KU\u002FL and\u002For BAT confirming hazelnut allergy diagnosis iii) Individuals allergic to seeds (sesame, flax, pumpkin, sunflower): Allergy to sesame defined by a suggestive clinical history of IgE-mediated sesame allergy and positive SPT to sesame (≥ 6 mm) and\u002For IgE to sesame and\u002For molecular components (Ses i 1 to Ses i 7) \\> 0.35 KU\u002FL and\u002For BAT confirming sesame allergy diagnosis OR Allergy to flaxseed defined by a suggestive clinical history of IgE-mediated flaxseed allergy and positive SPT to flaxseed (≥ 6 mm) and\u002For IgE to flaxseed \\> 0.35 KU\u002FL and\u002For BAT confirming flaxseed allergy diagnosis OR Allergy to pumpkin seed defined by a suggestive clinical history of IgE-mediated pumpkin seed allergy and positive SPT to pumpkin seed (≥ 6 mm) and\u002For IgE to pumpkin seed \\> 0.35 KU\u002FL and\u002For BAT confirming pumpkin seed allergy diagnosis OR Allergy to sunflower seed defined by a suggestive clinical history of IgE-mediated sunflower seed allergy and positive SPT to sunflower seed (≥ 6 mm) and\u002For IgE to sunflower seed \\> 0.35 KU\u002FL and\u002For BAT confirming sunflower seed allergy diagnosis\n* Patients referred to the Allergy Unit at Angers University Hospital (CHU d'Angers) for skin prick testing, either in outpatient consultation or during hospitalization\n* Patients affiliated with or beneficiaries of a social security system\n* Patient or legal representative having signed an informed consent form\n\nExclusion Criteria:\n\n* Pregnant women or women in labor\n* Individuals deprived of liberty by an administrative or judicial decision\n* Individuals undergoing involuntary psychiatric care\n* Adults under a legal protection measure\n* Individuals unable to express their consent\n* Poor understanding of the French language\n* Patients whose skin reactivity prevents the interpretation of the tests","2 Years",{"count":137,"type":23},35,[26],"Cannabis sativa is an annual herbaceous plant from the Cannabaceae family that has been cultivated and consumed by humans for thousands of years. Its main uses include fiber production, seeds for human and animal food, and psychoactive medications. Indeed, cannabis is the most commonly consumed illicit substance among adolescents and poses a major public health issue. Allergic risks associated with cannabis have already been documented.\n\nAt the same time, the consumption of hemp seeds is increasing due to the current agro-food context and the rise of vegan and vegetarian diets. This new food raises questions about its potential allergic risks, especially since the prevalence and severity of food allergies have been steadily increasing over the years. In this context, cases of anaphylaxis related to hemp seeds have already been reported. However, the potential allergic risk associated with hemp seeds remains largely unstudied to date.\n\nSeveral reasons make research into hemp seed allergies relevant:\n\ni) increased exposure to Cannabis sativa in its various forms, with the possibility of finding identical or similar proteins in the seeds; ii) changes in dietary habits, with the vegan trend encouraging the consumption of many seeds, including hemp seeds.",[29,141],"Allergens",[143],"Hemp seed","2026-06-11",{"date":146,"type":67},"2026-06-17",{"date":148,"type":23},"2026-09",{"date":150,"type":23},"2029-03",{"name":152,"class":153},"University Hospital, Angers","OTHER_GOV",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":24,"phases":164,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":177,"leadSponsor":179,"locationsCount":75},"100626381","early-phase-1-repeated-cbd-administration-and-cannabis-outcomes-100626381","NCT07434895","Repeated CBD Administration and Cannabis Outcomes","The Effects of Repeated CBD Administration on Cannabis Abuse Liability and Analgesia: A Human Laboratory Study","Inclusion Criteria:\n\n* English-speaking, literate adults,\n* Male or female,\n* Between the ages of 18-55,\n* Body Mass Index from 18.5-32.0 kg\u002Fm2,\n* Not currently seeking treatment for cannabis or drug use,\n* Able to provide written informed consent and perform all study procedures,\n* If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),\n* Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and\n* Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries.\n\nExclusion Criteria:\n\n* Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and\u002For alcohol that would require medical management,\n* Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \\[e.g., asthma, COPD\\]),\n* Current or past history of major psychiatric disorder that would limit ability to participate in the study,\n* Use of cannabis exclusively for medical reasons (no recreational use reported),\n* Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),\n* Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,\n* Clinically significant abnormal ECG (as determined by study physician\u002Fcardiologist),\n* Clinically significant abnormal laboratory findings,\n* History of seizure disorder,\n* Clinically significant history of head injuries requiring medical management or long lasting sequalae, and\n* Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice).","55 Years",{"count":163,"type":23},23,[165],"EARLY_PHASE1","This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.",[29,168,169],"Abuse Liability","Experimental Pain in Healthy Human Participants",[38,171,172],"cannabidiol (CBD)","marijuana users","2026-06-08",{"date":175,"type":67},"2026-06-10",{"date":119,"type":23},{"date":178,"type":23},"2029-12-01",{"name":180,"class":74},"Hannah Harris",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":161,"enrollmentInfo":188,"targetDuration":4,"studyType":24,"phases":190,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":205,"locationsCount":75},"100637962","phase-1-the-pharmacokinetics-of-a-hemp-based-topical-product-100637962","NCT07603518","The Pharmacokinetics of a Hemp-Based Topical Product","The Pharmacokinetics of a Hemp-Based Topical Cannabinoid Product in a Sanitized and Controlled Environment","Inclusion Criteria:\n\n* Have provided written informed consent\n* Be between the ages of 18 and 55\n* Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests\n* Test negative for recent cannabis use in urine at the screening visit and again upon admission for the inpatient stay.\n* Test negative for other drugs of abuse, including alcohol, at the screening visit and again upon admission for the inpatient stay.\n* Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit.\n* Have a body mass index (BMI) in the range of 18 to 38 kg\u002Fm2\n* Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg\n* Report prior experience using cannabis or CBD products.\n\nExclusion Criteria:\n\n* Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the screening visit.\n* History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.\n* Current use of medications which, in the opinion of the investigator or medical monitor, will interfere with the study results or the safety of the subject.\n* History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples.\n* Known allergy to any ingredients in the study drug.\n* Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.",{"count":189,"type":23},20,[191],"PHASE1","This study will evaluate the pharmacokinetic effects of acute and chronic dosing of a hemp-based cannabidiol (CBD) topical lotion with low levels of delta-9-tetrahydrocannabinol (THC) in a sanitized and controlled environment.",[29],[195,196,197,198],"Cannabinoids","Pharmacology","Contamination","Hemp lotion","2026-05-18",{"date":201,"type":67},"2026-05-22",{"date":203,"type":23},"2026-06",{"date":148,"type":23},{"name":206,"class":74},"Johns Hopkins University",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":18,"minAge":215,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":24,"phases":218,"briefSummary":220,"conditions":221,"keywords":225,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":5},"100487639","phase-2-aristocrat-blinded-trial-of-temozolomide---cannabinoids-100487639","NCT05629702","ARISTOCRAT: Blinded Trial of Temozolomide +\u002F- Cannabinoids","A Randomised Controlled Phase II Trial of Temozolomide With or Without Cannabinoids in Patients With Recurrent Glioblastoma","ARISTOCRAT","Inclusion Criteria:\n\n* Histological diagnosis of MGMT promoter methylated, IDH wild type (WT) GBM with consistent local molecular pathology (repeat biopsy at recurrence is NOT required).\n* First recurrence of GBM planned for systemic treatment as determined by local Multidisciplinary Team (MDT), including agreement of a Consultant Neuro-Radiologist that imaging changes are most in keeping with recurrence and not pseudo-progression. Patients with a prior recurrence treated by surgical resection alone are eligible at time of first recurrence planned for systemic treatment.\n* Patients must have received initial first-line treatment with standard dose conventionally fractionated radiotherapy (i.e. 40 Gy in 15 fractions or 54-60 Gy in 28-33 fractions; other regimes may be considered in consultation with the ARISTOCRAT Trial Office) with concomitant and adjuvant TMZ.\n\n  * A minimum of 3 cycles of adjuvant TMZ must have been received.\n  * A minimum of Stable Disease (SD) (or Partial Response (PR)\u002FComplete Response (CR)) at the end of first-line treatment (measured by Response Assessment for Neuro-Oncology (RANO) criteria).\n* ≥3 months since day 28 of the last cycle of TMZ.\n* Karnofsky Performance Status ≥60.\n* Adequate hematologic, renal, and hepatic function within 14 days prior to randomisation:\n\n  * Absolute neutrophil count (ANC) ≥1.5 x 109\u002FL\n  * Platelet count ≥100 x 109\u002FL\n  * Serum creatinine clearance (measured or calculated (using local standard practice)) \\>30ml\u002Fmin\n  * Total serum bilirubin ≤1.5 x upper limit of normal (ULN)\n  * Liver transaminases \\\u003C2.5 x ULN\n* If surgery has been performed for first recurrence, then the wound must be adequately healed and there must be residual enhancing disease on MRI within 21 days of surgery or new enhancement at later follow up deemed suitable for systemic treatment.\n* Recovered from previous treatment side-effects ≤ Grade 2.\n* If on systemic steroids, must be on stable (≥7 days) or decreasing dose of steroids.\n* Willing and able to provide trial-specific informed consent.\n* Willing and able to comply with trial requirements.\n* Age ≥16.\n* Able to start treatment within 28 days of randomisation.\n\nExclusion Criteria:\n\n* Pathology inconsistent with IDH WT GBM (e.g. patients with molecular features of PXA or BRAF mutation will be excluded).\n* Prior invasive malignancy (except non-melanoma skin cancer), unless disease free for a minimum of one year.\n* Prior treatment with stereotactic radiotherapy, brachytherapy or Convection Enhanced Delivery (CED) of any agent.\n* Prior treatment, apart from debulking surgery, for first recurrence of GBM.\n* Any active co-morbidity making patient unsuitable for trial treatment in the view of the Investigator.\n* Personal history of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric diagnosis other than depression associated with their underlying glioma condition.\n* Prior allergic reaction or significant toxicity (≥Grade 3 CTCAE) related to TMZ treatment.\n* Current or recent cannabis or cannabinoid-based medications within 28 days of randomisation and\u002For unwilling to abstain for the duration of the trial.\n* Women who are pregnant, breastfeeding or a woman of childbearing potential who is unwilling to use effective contraceptive methods during trial treatment and for 6 months after completion of trial treatment.\n\n  o Women of childbearing age must have a negative pregnancy test within 7 days prior to randomisation.\n* Men who are sexually active and unwilling\u002Funable to use medically acceptable forms of contraception during trial treatment or for 6 months after completion of trial treatment.\n* Contra-indication to MRI or gadolinium.\n* Hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.\n* Known hypersensitivity to cannabinoids or excipients of the IMP.\n* Known history of current or prior alcohol or drug dependence.\n* Known Hepatitis B (HBV), Cytomegalovirus (CMV) or opportunistic infection.\n* Has received a live vaccine within 28 days prior to randomisation.\n* Unable to administer oromucosal medication due to mucosal lesions or other issues.\n* Participation in another therapeutic clinical trial whilst taking part in this trial.\n* Any psychological, familial, sociological or geographical condition hampering protocol compliance.","16 Years",{"count":217,"type":23},120,[219],"PHASE2","ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to compare the cannabinoid Nabiximols with placebo in patients with recurrent MGMT methylated glioblastoma (GBM) treated with temozolomide (TMZ).",[222,223,29,224],"Glioblastoma","Brain Tumor","Brain Tumor, Recurrent",[226,227,228,229,230,31,231,232,233],"cannabinoid","GBM","temozolomide","sativex","nabiximols","glioblastoma","brain","recurrent","2026-04-29",{"date":236,"type":67},"2026-05-05",{"date":238,"type":67},"2023-02-03",{"date":240,"type":23},"2027-04",{"name":242,"class":74},"University of Birmingham",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":17,"sex":18,"minAge":109,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":24,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":75},"100478816","phase-2-effects-of-cannabidiol-and-tetrahydrocannabinol-on-microbiome-and-neuroinflammation-in-hiv-100478816","NCT05514899","Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV","Effects of Cannabidiol and Tetrahydrocannabinol on the Microbiome, Endocannabinoids, and Neuroinflammation in HIV","CAMI","1. Aged 21 to 70 years old\n2. Possess the capacity to provide informed consent to a set of neuromedical assessment procedures.\n3. Experience with cannabis use at least once in the past 5 years without major adverse effects (e.g., psychosis, syncope)\n4. No or low cannabis use in the past 2 weeks, defined as no cannabis exposure or use or use limited to only once in the past 2 weeks.\n5. Willing to abstain from use of cannabis, CBD, THC, or synthetic cannabinoids outside the study during the 6-week intervention\n6. Individuals with HIV must meet the following criteria\n\n   1. Virally suppressed on stable ART for at least 6 months and have no more than 1 prior event of virologic failure (i.e., required change in ARTs due to virologic failure)\n   2. Stage 1 or 2 infection\n   3. Have a \"normal\" CD4 count defined as ≥350 cells\u002Fmicroliter\n   4. No significant history of ART regimen adherence challenges\n7. Ability to adhere to the study visit schedule.\n\nExclusion Criteria:\n\n1. Exclusion criteria will be: any substance use disorder (abuse or dependence) other than cannabis in the last 30 days;\n2. Significant cognitive impairment such as Dementia, including Alzheimer's disease\n3. Pregnancy or lactation, or unwillingness to prevent pregnancy during the trial; refusal to maintain highly effective contraceptive methods (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner) during the study for persons of child-bearing potential or those with partners of child-bearing potential\n4. Evidence of moderately or worse compromised liver or kidney function, including moderate (Child-Hugh B) or severe (Child-Hugh C) hepatic impairment and AST and ALT above ULN and total bilirubin above ULN;\n5. Evidence of significant cardiovascular risk, resting heart rate \\\u003C50 or \\>110 beats per minute, uncontrolled hypertension (systolic blood pressure \\\u003C80 or \\>140 mmHg; diastolic blood pressure \\\u003C50 or \\>90 mmHg), history of myocardial infarction, congestive heart failure, or arrhythmia);\n6. Evidence of chronic pulmonary disease requiring supplemental oxygen;\n7. Active, recent, or remote medical history of hepatobiliary-related illness, including elevated transaminase levels above 3 times the upper limit of normal accompanied by elevations in total bilirubin above 2 times the upper limit of normal at screening;\n8. Insulin dependent diabetics\n9. Allergy to the study drugs or any of their constituents including sesame\n10. Use of medications with absolute contraindicated or potential significant interactions\n11. Use of sedating medications\n12. Weighing less than 60 kg at screening to minimize the risk of elevated transaminases as a result of exposure to cannabidiol;\n13. Active, uncontrolled psychiatric disorder with psychotic features, severe depression, or suicidality; Participants will be excluded if they have had a history of suicide attempt, recent suicidal ideation or behavior as indexed by their Beck Depression Inventory-II (BDI-II) score is greater than or equal to 29 (severe depression).\n14. Neurologic disorder that could compromise interpretation of study findings, including uncontrolled seizure disorder (active seizures within the past 3 months), multiple sclerosis, Parkinson's disease, Alzheimer's disease, and recent (past 3 months) cerebral infarction or hemorrhage with neurological sequelae.","70 Years",{"count":253,"type":23},90,[219],"This study has the potential to contribute to a more complete understanding of the independent and combined effects of cannabis use and HIV on the brain and on inflammation. Such knowledge may inform future strategies for treating brain disease and inflammation. Participants will be randomly assigned to one of two groups, both of which will receive the same treatment in a different order over a period of about 6 weeks. The visits include physical examinations, blood tests, and other procedures designed to monitor subject safety and measure the effects of the study drug.",[257,29,258,259,260,261],"HIV","THC","Neuroinflammatory Disease","Neuroinflammatory Response","Microbiome","2026-04-27",{"date":264,"type":67},"2026-05-01",{"date":266,"type":67},"2023-09-01",{"date":268,"type":23},"2027-10-31",{"name":270,"class":74},"University of California, San Diego",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":161,"enrollmentInfo":278,"targetDuration":4,"studyType":24,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":75},"100416561","phase-1-gender-related-differences-in-the-acute-effects-of-delta-9-tetrahydrocannabinol-in-healthy-humans-sub-study-ii-100416561","NCT04704271","Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II","THC-Gender-II","Inclusion Criteria:\n\n* At least one lifetime exposure to cannabis\n* Good physical and mental health\n\nExclusion Criteria:\n\n* Cannabis naïve individuals\n* Major current or recent stressors",{"count":279,"type":23},100,[191],"The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.",[29],"2026-04-23",{"date":234,"type":67},{"date":286,"type":67},"2019-10-09",{"date":288,"type":23},"2027-12-01",{"name":290,"class":74},"Yale University",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":24,"phases":301,"briefSummary":303,"conditions":304,"keywords":307,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":75},"100552485","phase-3-reducing-breathlessness-with-dronabinol-in-copd-patients-100552485","NCT06473701","Reducing Breathlessness With Dronabinol in COPD Patients","BONG: Reducing Severe Breathlessness With Dronabinol in the Severe and Very Severe Chronic Obstructive Pulmonary Disease Patient Group - A Randomized, Double-Blind, Placebo-Controlled, Crossover Study","BONG","Inclusion Criteria:\n\n* Refractory dyspnea despite optimal treatment\n* COPD (GOLD 3,4)\n* Breathlessness corresponding to mMRC score ≥ 3\n* Informed written consent\n* Age ≥ 18 years\n* Cognitive relevant, of legal age\n* Understands and speaks Danish\n* For fertile women defined by amenorrhea for less than 12 months: negative HCG before entry into the trial\n* For fertile and sexually active subjects: use of safe contraception during medication intake and 4 weeks after: intrauterine device (IUD) or hormonal contraception (oral contraceptive pill, implant, transdermal patch, vaginal ring or depot injection).\n\nExclusion Criteria:\n\n* Ongoing infection or exacerbation of COPD within the last month (30 days)\n* Regular treatment with THC or CBD within 1 month (30 days)\n* Life expectancy less than 3 months (90 days)\n* Treatment with medicines that, according to the summary of product characteristics, are strong inhibitors or inducers of CYP3A4, CYP2C9 or CYP2C19\n* History of or current evidence of significant medical or psychiatric disorder that is considered by the investigator to put the subject at greater risk of experiencing an adverse event\n* Current or past substance abuse where the investigator finds it too risky for the subject to be included in the study",{"count":300,"type":23},30,[302],"PHASE3","This clinical trial examines whether Dronabinol, which contains the synthetic psychoactive compound tetrahydrocannabinol (THC), can alleviate severe breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (COPD).",[305,306,29],"COPD","Breathlessness",[308,309,29,305,306],"Randomized, Controlled, Double-blind, Crossover trial","Cannabis-based medicine","2026-04-16",{"date":312,"type":67},"2026-04-17",{"date":314,"type":67},"2025-02-26",{"date":316,"type":23},"2026-10",{"name":318,"class":74},"Vejle Hospital",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":17,"sex":18,"minAge":326,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":24,"phases":330,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":342,"locationsCount":75},"100424742","modeling-the-effects-of-chronic-marijuana-use-on-neuroinflammation-and-hiv-related-neuronal-injury-100424742","NCT04810858","Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury","CHI","Inclusion Criteria:\n\n* verified HIV status\n* Current marijuana use (MJ+ groups only)\n* No current marijuana use (MJ- groups only)\n* current engagement in HIV care (HIV+ participants only)\n* receipt of cART as first-line of treatment (HIV+ participants only)\n* stable cART regimen (HIV+ participants only)\n* undetectable HIV RNA viral load for \\>1 year (HIV+ participants only)\n\nExclusion Criteria:\n\n* Lifetime abuse for any illicit drug other than marijuana\n* \\\u003C9th grade education; illiteracy or lack of fluency in English\n* history of moderate or severe head trauma\n* unstable or serious neurological disorders\n* severe mental illness\n* systemic autoimmune diseases\n* immunotherapy\n* MRI contraindications","25 Years","59 Years",{"count":329,"type":23},220,[26],"This study applies a hypothesis-driven approach to examine the effects of chronic marijuana use on HIV-associated inflammation and its subsequent impacts on central nervous system function, with the goal of identifying the mechanisms through which cannabinoids modulate neurological disorders and other comorbidities in persons with HIV.",[29,257,333,334,335],"Inflammation","Cognition","Neuroimaging","2026-03-27",{"date":338,"type":67},"2026-03-31",{"date":340,"type":67},"2021-08-18",{"date":125,"type":23},{"name":343,"class":74},"Wake Forest University Health Sciences",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":17,"sex":18,"minAge":352,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":24,"phases":356,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":75},"100387532","age-differences-in-the-effects-of-cannabis-on-simulated-driving-100387532","NCT04325958","Age Differences in the Effects of Cannabis on Simulated Driving","The Influence of Age on Driving-related Cannabis Effects: Exploring Cannabis Use Frequency and Related Factors","ADCUF","Inclusion Criteria\n\n* 19-25 or 35-45 years of age;\n* Use of smoked cannabis at least once in the past 6 months.\n* Use of smoked or vaped cannabis primarily for recreational purposes on up to 1 day per week or on at least 6 days per week in the past 3 months;\n* Holds a class G or G2 Ontario driver's licence (or equivalent from another jurisdiction) for at least 12 months;\n* Willing to abstain from using alcohol for 24 hours and cannabis for 72 hours prior to Practice and Test Sessions;\n* Willing to abstain from all other drugs not prescribed for medical purposes for 48 hours prior to Practice and Test Sessions;\n* Resides within Toronto (study site) or can reside with friends\u002Ffamily in Toronto after a Test Session; this area may be extended to the Greater Toronto area if recruitment challenges arise;\n* Participant willing to use appropriate contraception until their participation in the study is completed;\n* Provides written and informed consent.\n\nExclusion Criteria\n\n* Use of cannabis primarily for therapeutic purposes, or equally for therapeutic and recreational purposes;\n* Diagnosis of medical condition that contraindicates use of cannabis determined by self-report as judged by the Principal Investigator and a study physician; this includes a history of hypersensitivity to cannabinoids smoke, respiratory disease and\u002For severe cardiovascular, cerebrovascular, renal or liver disease, and bleeding disorders. Smoking cannabis is not recommended for individuals with respiratory diseases, and they will be excluded;\n* Diagnosis of psychiatric condition that contraindicates use of cannabis determined by self-report or SCID-5;\n* Participants of childbearing potential: Pregnancy (point-of-care test) or breastfeeding;\n* Meets criteria for current or lifetime alcohol or other substance use disorder (DSM-5), except tobacco use disorder and caffeine use disorder;\n* Is a regular user of medications that affect brain function (based on self-report); this includes concomitant therapy with sedative-hypnotics or other psychoactive drugs\n* Use of anti-hypertensives;\n* First-degree relative diagnosed with schizophrenia or another psychotic disorder.\n* Participation in a past driving study at CAMH (to limit practice effects).\n* Participation in a clinical study concurrent with their participation in this study.","19 Years","45 Years",{"count":355,"type":23},128,[26],"Epidemiological studies suggest that the use of cannabis is associated with an increase in the risk of motor vehicle collisions. It is also known that younger users may be at increased risk for motor vehicle collisions. Further, the frequency with which cannabis is used may be an important variable in determining the effects of cannabis on driving. The purpose of the present study will be to investigate the effects of cannabis on simulated driving in young as compared to middle-aged drivers. Half of the participants will be occasional users of cannabis and half will be frequent users of cannabis.",[29],"2026-03-20",{"date":361,"type":67},"2026-03-23",{"date":363,"type":67},"2024-03-27",{"date":365,"type":23},"2027-03",{"name":367,"class":74},"Centre for Addiction and Mental Health",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":17,"sex":375,"minAge":19,"maxAge":110,"enrollmentInfo":376,"targetDuration":4,"studyType":24,"phases":378,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":75},"100625009","sex-hormones-impact-on-cannabis-response-100625009","NCT07417059","Sex Hormones Impact on Cannabis Response","The Influence of Female Sex Hormones on the Subjective and Cognitive Response to Cannabis","Inclusion Criteria:\n\n* Biological female\n* Used cannabis between 1 time a month and 2 times a week during the previous year\n* Age between 18 and 40 years\n* Free from psychotropic medication\n* Free from hormonal birth control\n* A regular menstrual cycle (last 3 cycles a duration between 21 and 35 days).\n* Good physical health as determined by medical examination and laboratory analysis\n* Absence of any major medical, endocrine and neurological condition as determined by medical examination and laboratory analysis\n* Normal weight, body mass index (weight\u002Fheight2) between 18 and 28 kg\u002Fm2\n* Written Informed Consent\n* Good knowledge and understanding of the English language\n* Participants must be willing to refrain from taking illicit psychoactive substances during the study.\n* Participants must be willing to drink only alcohol-free liquids and no coffee, black or green tea, or energy drinks after midnight of the evening before the study session, as well as during the study day.\n* Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after substance administration.\n\nExclusion Criteria:\n\n* History of drug addiction (determined by the medical questionnaire, drug questionnaire and medical examination)\n* Pregnancy or lactation or pregnancy planned during study participation\n* Hypertension (diastolic \\> 90 mmHg; systolic \\> 140 mmHg)\n* Current or history of psychiatric disorder (determined by the medical questionnaire and medical examination)\n* Current presence or history of psychosis in first-degree relatives\n* Any chronic or acute medical condition\n* History of cardiac dysfunctions (arrhythmia, ischemic heart disease,…)\n* Tobacco smoking (\\>20 per day)\n* Excessive drinking (\\>20 alcoholic consumptions per week)","FEMALE",{"count":377,"type":23},21,[26],"The goal of this study is to systematically determine whether the cannabis response in human females is related to SH fluctuations throughout the menstrual cycle.",[29],[382,31,258],"sex hormones","2026-02-10",{"date":385,"type":67},"2026-02-18",{"date":387,"type":67},"2025-06-01",{"date":389,"type":23},"2026-12-31",{"name":391,"class":74},"Maastricht University",{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":17,"sex":18,"minAge":109,"maxAge":20,"enrollmentInfo":399,"targetDuration":4,"studyType":24,"phases":401,"briefSummary":402,"conditions":403,"keywords":408,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":75},"100516043","phase-2-understanding-the-clinical-pharmacology-of-marijuana-tobacco-co-administration-100516043","NCT05999383","Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration","CANNIC","Inclusion Criteria:\n\n* Heart rate \\\u003C 105 beats per minute (BPM)\\*\n* Systolic Blood Pressure \\\u003C 160 and \\> 90\\*\n* Diastolic Blood Pressure \\\u003C 100 and \\> 50\\*\n\n  \\*Considered out of range if both machine and manual readings are above\u002Fbelow these thresholds.\n* Body Mass Index (BMI) ≤ 38.0 (at investigator's discretion for higher BMI if no other concurrent health issues)\n* Current regular user of cannabis who smokes or vapes cannabis or THC extracts at least three days a week for the past 3 months or more\n* Test positive for D-9-tetrahydrocannabinol (THC) at screening and self-report of cannabis use\n* Current user of inhaled forms of tobacco\u002Fnicotine (cigarette, cigars, e-cigarettes) who use the product daily for the past 3 months or more\n* Saliva cotinine ≥ 30 ng\u002FmL\n\nExclusion Criteria:\n\n* Unstable medical conditions:\n\n  * Heart disease\n  * Seizures\n  * Cancer\n  * Thyroid disease (okay if controlled with medication)\n  * Diabetes\n  * Hepatitis B or C or Liver disease\n  * Glaucoma\n  * Kidney disease or urinary retention\n  * An ulcer in the past year\n  * Active use of an inhaler for asthma or Chronic Obstructive Pulmonary Disease (COPD)\n* Hypertension if uncontrolled (meaning participant has a diagnosis, but they are not taking medication\u002Funder treatment (e.g., diet or exercise plan)\n* Drug\u002FAlcohol Dependence\n\n  * Alcohol or illicit drug dependence within the past 12 months (currently in treatment) with the exception of those who recently completed an alcohol\u002Fdrug treatment program\n  * Positive toxicology test at the screening visit (THC \\& prescribed medications okay)\n  * Opioid replacement therapy (including methadone, buprenorphine, or other)\n* Psychiatric conditions\n\n  * Current or past schizophrenia, and\u002For current or past bipolar disorder\n  * Major depression, current or within the past year\n  * Major personality disorder\n  * Participants with current or past minor or moderate depression and\u002For anxiety disorders will be reviewed by the PI \\[study physician\\] and considered for inclusion\n  * History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per PI's \\[study physician's\\] approval\n* Current regular use of any psychiatric medications with the exception of Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) and current evaluation by the PI that the participant is otherwise healthy, stable, and able to participate\n* Congenital or acquired immunodeficiency disorders (i.e. HIV, congenital immune deficiency syndrome, chronic diseases)\n* Other disorders (i.e. ICU, malnutrition, immunosuppressive therapy)\n* Traumatic brain injury\n* Recent onset or change (worsening) in cough, fever and\u002For abdominal symptoms (vomiting or pain) in the past two weeks\n* Medications\n\n  * Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs)\n  * Concurrent use of nicotine-containing medications\n  * Any stimulant medications (ex. Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment\n* Other\u002FMisc. Chronic Health Problems\n\n  * Oral thrush\n  * Fainting\n  * Other \"life threatening illnesses\" as per study physician's discretion\n* Pregnancy\n\n  * Pregnancy (self-reported and urine pregnancy test)\n  * Breastfeeding (determined by self-report)\n* Concurrent participation in another clinical trial\n* Inability to communicate in English\n* History of marijuana-induced psychosis or paranoia after smoking marijuana\n* Scoring a 7 or higher on the Severity of Dependence Scale (SDS) for cannabis use\n* Planning to quit smoking or vaping within the next 60 days\n* Planning to quit cannabis use within the next 60 days\n* Uncomfortable with getting blood drawn\n* Willingness to abstain from tobacco smoking and all combustible products for 13 hours before admission\n* Willingness to abstain from smoking\u002Fingestion of cannabis 13 hours before\n* Willingness to abstain from nicotine products 13 hours before each admission",{"count":400,"type":23},48,[219],"This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.",[258,29,404,405,406,407],"Cannabis Use","Cannabis Smoking","Tobacco Use","Vaping",[258,29,409,410,411],"Marijuana","Nicotine","Vape","2026-01-05",{"date":414,"type":67},"2026-01-07",{"date":416,"type":67},"2025-07-01",{"date":418,"type":23},"2028-02-01",{"name":420,"class":74},"University of California, San Francisco",{"id":422,"slug":423,"hasResults":11,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":17,"sex":18,"minAge":109,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":24,"phases":431,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":440,"locationsCount":75},"100523721","phase-1-modulation-of-thc-effects-by-cbd-a-dose-ranging-study-100523721","NCT06099379","Modulation of THC Effects by CBD: a Dose-ranging Study","Modulation of ∆9-tetrahydrocannabinol Acute Psychoactive Effects by Ranging Doses of Cannabidiol in Healthy, Occasional Cannabis Users: a Controlled, Triple Blind, Randomized, Cross-over Study","SPECTRE","Inclusion Criteria:\n\n1. Between 21 and 49 years of age, inclusively;\n2. Have used cannabis at least once in their lifetime and have used cannabis three days or less in the 30 days prior to enrollment;\n3. Be able to provide a signed informed consent;\n4. Willing to comply with study procedures and requirements as per protocol;\n5. Have a forced expiratory volume in first second (FEV) less than or equal to 90 %;\n6. Able to communicate and understand English or French language;\n7. For female participants:\n\n   a. No childbearing potential, defined as: i. postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or ii. Documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or b. For female of childbearing potential: i. Must have negative pregnancy test result at screening and at subsequent visits.\n\nii. AND have no pregnancy plan while on the study iii. AND must agree to use a medically accepted method of birth control throughout the study.\n\nExclusion criteria\n\nParticipants will be excluded if any of the following criteria are met:\n\n1. Any disabling medical condition, as assessed by medical history, physical exam, vital signs and\u002For laboratory assessments that, in the opinion of the study physician, precludes safe participation in the study or the ability to provide fully informed consent;\n2. Severe psychiatric condition (history of schizophrenia, schizoaffective disorder or bipolar disorder; current acute psychosis, mania or current suicidality based on the Mini International Neuropsychiatric Interview);\n3. Any other disabling, unstable or acute mental condition that, in the opinion of the study physician, precludes safe participation in the study or ability to provide fully informed consent;\n4. Known chronic liver disease or aspartate transaminase\u002Falanine transaminase (AST\u002FALT) two times higher than upper limit of normal values at screening visit;\n5. Blood pressure higher than 130\u002F80 mmHg;\n6. Kidney disorders;\n7. Bleeding disorders;\n8. Current moderate or severe DSM-5 substance use disorder (except nicotine) according to SCID-V;\n9. Currently pregnant, breastfeeding or planning to become pregnant either at screening or while enrolled in the study;\n10. Pending legal action or other reason that, in the opinion of the study physician, might prevent study completion;\n11. Use of medication within 7 days of experimental sessions; which, in the opinion of the Investigator, may interact with cannabis.\n12. Participation in clinical studies or undergoing other investigational procedure involving cannabis or cannabinoids administration within 30 days prior to randomization.\n13. Resting heart rate over 100 beats per minute.\n14. Current body mass index (BMI) over 29.9 kg\u002Fm2.\n15. Any clinically significant electrocardiogram abnormalities at screening visit.","49 Years",{"count":279,"type":23},[191,219],"The purposes of this study are 1) to determine if CBD modulates THC-induced acute psychoactive effects at different CBD:THC ratios, compared with the control product (0:20, 20:20, 40:20, 80:20, 120:20) and 2) to determine if different doses of CBD modulate other THC induced behavioral effects, compared with the control product and 3)To explore qualitatively whether CBD modulates THC effects by mechanisms that are not detected with standard clinical research tools.",[29,258],"2025-12-16",{"date":436,"type":67},"2025-12-22",{"date":438,"type":67},"2024-06-27",{"date":389,"type":23},{"name":441,"class":74},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":17,"sex":18,"minAge":109,"maxAge":429,"enrollmentInfo":449,"targetDuration":4,"studyType":24,"phases":451,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":456,"leadSponsor":458,"locationsCount":4},"100463874","phase-1-a-study-of-inhaled-cannabidiol-in-healthy-occasional-cannabis-users-100463874","NCT05320367","A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users","A Randomized, Triple Blinded Cross-over Placebo Controlled Study of Effects of Inhaled Cannabidiol in Healthy Occasional Cannabis Users","Inclusion Criteria:\n\n1. Between 21 and 49 years of age, inclusively;\n2. Have used cannabis at least once in lifetime AND have used cannabis three days or less in the 28 days prior to enrollment;\n3. Be able to provide a signed informed consent;\n4. Willing to comply with study procedures and requirements as per protocol, including to abstain from using other cannabis products or any drugs (except alcohol or nicotine) 7 days prior to study visits;\n5. Have a forced expiratory volume in first second (FEV) sup 90 %;\n6. Able to communicate and understand English or French language;\n7. For female participants:\n\n   a. Without childbearing potential, defined as: i. postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or ii. Documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or\n\n   b. With childbearing potential: i. Must have negative pregnancy test result at screening and at subsequent visits.\n\nii. AND have no pregnancy plan while on the trial iii. AND must agree to use a medically accepted method of birth control throughout the study.\n\nExclusion Criteria:\n\n1. Any disabling medical conditions, as assessed by medical history, physical exam, vital signs and\u002For laboratory assessments that, in the opinion of the study physician, precludes safe participation in the study or the ability to provide fully informed consent;\n2. Severe psychiatric condition (e.g. history of schizophrenia, schizoaffective disorder or bipolar disorder; current acute psychosis, mania or current suicidality, acute depression or anxiety disorder based on the Mini International Neuropsychiatric Interview);\n3. Any other disabling, unstable, or acute mental condition that, in the opinion of the study physician, precludes safe participation in the study or ability to provide informed consent;\n4. Known chronic liver disease or aspartate transaminase\u002Falanine transaminase (AST\u002FALT) two times higher than upper limit of normal values at screening visit;\n5. Blood pressure higher than 130\u002F80 mmHg;\n6. Kidney disorders;\n7. Bleeding disorders;\n8. Current moderate or severe DSM-5 (The Diagnostic and Statistical Manual of Mental Disorders) substance use disorder (except nicotine) according to the Structured Clinical Interview for DSM-V ;\n9. Currently pregnant,breastfeeding or planning to become pregnant either at screening or while enrolled in the study;\n10. Pending legal action or other reason that, in the opinion of the study physician, might prevent study completion;\n11. Use of medication within 7 days of experimental sessions, which, in the opinion of the investigator, may interact with cannabis;\n12. Participation in clinical studies or undergoing other investigational procedures involving cannabis or cannabinoids administration within 30 days prior to randomization;\n13. Resting heart rate over 100 beats per minute;\n14. Current body mass index (BMI) over 29.9 kg\u002Fm2;\n15. Any clinically significant electrocardiogram abnormalities at screening visit.",{"count":450,"type":23},80,[191,219],"The purposes of this study are 1) to determine if the administration of different low doses of CBD (5 mg, 20 mg, 50 mg and 100 mg) result in detectable subjective pleasant drug effect compared to placebo and 2) to qualitatively explore whether low dose CBD is associated with effects that are not detected with the available research tools.",[29],{"date":436,"type":67},{"date":148,"type":23},{"date":457,"type":23},"2027-12",{"name":441,"class":74},{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":251,"enrollmentInfo":466,"targetDuration":4,"studyType":24,"phases":468,"briefSummary":469,"conditions":470,"keywords":472,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":75},"100425212","phase-3-effect-of-cannabis-extract-on-acute-radicular-pain-and-on-analgesic-requirement-100425212","NCT04816994","Effect of Cannabis Extract on Acute Radicular Pain and on Analgesic Requirement","Effect of Cannabis Extract on Acute Radicular Pain and on Analgesic Requirement: A Double Blinded, Randomized, 24 Hours Follow-up Study","Inclusion Criteria:\n\n* Age 18 - 70 years\n* ASA 1 or 2\n* Acute Radicular Pain \\\u003C 12 weeks\n* Pain of VAS 6 or more\u002F VRS moderate or more\n* Radicular pain: Dermatomal pain that corresponds to physical exam and CT\u002FMRI in the last year\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or \\> 70 years\n* ASA 3 or more\n* Chronic radicular pain \\> 12 weeks\n* Past spine surgery\n* Intermittent Claudication due to Vascular Disease\n* Diagnosed Diabetic Neuropathy\n* Regular Cannabis use in past 6 months (more than once a week) OR once in last 2 weeks\n* Regular opioid use in past week (Targin, Percocet, Tramadol) (Equivalent to Oxycodone 20 mg\u002Fday or more)\n* Pregnancy or Lactating\n* Ischemic heart disease\n* Renal or hepatic failure\n* History of psychiatric illness\n* Cognitive impairment or inability to answer questions\n* Known allergy to opioids\n* Potential Loss to follow up",{"count":467,"type":23},200,[302],"Clinical evidence about the effects of cannabis in the management of acute pain is rather scarce, mostly consisting of case report-based opinions on adverse events during or after general anesthesia after smoking cannabis, experimental pain trials in healthy volunteers, and a few clinical trials using different drugs, dosages and routes of administration. It is difficult to draw strong conclusions from the available evidence, that may seem sometimes even contradictory, mainly due -the investigators believe- to the many sources of variability in the study designs (e.g.: heterogeneity of the study samples, underpowered, unblinding, lack of randomization, timing of the therapeutic intervention, different experimental pain models, inclusion of different kind of surgical pain, etc.). Nevertheless, expert's opinion after a critical review of the literature is that cannabis and cannabinoids may have a beneficial role in the management of acute pain, at least for a selected group of patients and through an appropriate therapeutic intervention.\n\nCannabis oil seem to be most suitable to our investigation. The co-administration of tetrahydrocannabinol (THC) with cannabidiol (CBD) may translate into additional therapeutic benefits with an attenuation of adverse effects. And will help treat acute radicular back pain and for renal colic.",[471,29],"Acute Radicular Back Pain",[473,29],"Acute radicular back pain","2025-09-29",{"date":476,"type":67},"2025-10-02",{"date":478,"type":67},"2018-01-07",{"date":480,"type":23},"2025-12-31",{"name":482,"class":74},"Hadassah Medical Organization",{"id":484,"slug":485,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":161,"enrollmentInfo":490,"targetDuration":4,"studyType":24,"phases":492,"briefSummary":281,"conditions":493,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":75},"100271319","phase-1-gender-related-differences-in-the-acute-effects-of-delta-9-tetrahydrocannabinol-in-healthy-humans-sub-study-i-100271319","NCT02811510","Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I","THC-Gender-I","Inclusion Criteria:\n\n* At least one lifetime exposure to cannabis\n* Good physical and mental health\n\nExclusion Criteria:\n\n* Cannabis naive individuals\n* Major current or recent stressors\n* Taking estrogen supplements or oral contraceptive pills (for women)\n* Sesame oil allergy",{"count":491,"type":23},40,[191],[29],"2025-06-05",{"date":496,"type":67},"2025-06-10",{"date":498,"type":4},"2016-06",{"date":500,"type":23},"2026-12",{"name":290,"class":74},{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":161,"enrollmentInfo":509,"targetDuration":4,"studyType":24,"phases":510,"briefSummary":281,"conditions":511,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":516,"locationsCount":75},"100269022","phase-1-gender-related-differences-in-the-acute-effects-of-delta-9-tetrahydrocannabinol-in-healthy-humans-100269022","NCT02781519","Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans","THC-Gender","Inclusion Criteria:\n\n* at least one lifetime exposure to cannabis\n* good physical and mental health\n\nExclusion Criteria:\n\n* cannabis naive individuals\n* major current or recent stressors\n* taking estrogen supplements or oral contraceptive pills (for women)",{"count":279,"type":23},[191],[29],{"date":496,"type":67},{"date":514,"type":4},"2015-06",{"date":500,"type":23},{"name":290,"class":74},{"id":518,"slug":519,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":11,"sex":18,"minAge":326,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":24,"phases":527,"briefSummary":528,"conditions":529,"keywords":533,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":546,"locationsCount":75},"100515003","phase-2-evaluating-tetrahydrocannabinol-as-an-adjunct-to-opioid-agonist-therapy-100515003","NCT05985850","Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy","Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy for Individuals Living With Opioid Use Disorder: A Phase II, Placebo-controlled, Blinded, Pilot Study to Assess Safety and Feasibility (THC-MMT)","THC-MMT","Inclusion Criteria:\n\n1. Individuals of at least 25 years of age or older;\n2. Diagnosed with OUD as per DSM-5 criteria;\n3. Initiated or re-initiated methadone-based OAT within the past 30 days prior to study entry;\n4. Cannabis-use experienced, defined as having used any amount of cannabis in the six months prior to the screening visit;\n5. Willing to only use study-provided cannabis as directed by study protocol, including abstention from non-study cannabis and cannabinoids;\n6. Agree to keep all study medication stored in a secure location and not to share\u002Fdistribute study medication to any other individual;\n7. If assigned female sex at birth:\n\n   1. Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and over 45 years of age); or (ii) documented surgical sterilization (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or\n   2. If of childbearing potential, be willing to use an acceptable method of contraception throughout the study and have a negative pregnancy test at screening;\n8. Ability to understand and comply with study protocol procedures and to provide written informed consent.\n\nInclusion criteria for Phase 2\n\nIn addition to meeting all eligibility criteria outlined in Phase 1, participants will be eligible for Phase 2 provided they meet ALL the following criteria at Week 12:\n\n1. Participants who have not experienced a study medication-related serious adverse event during Phase 1;\n2. Participants who have not been lost to follow-up during Phase 1.\n\nExclusion Criteria:\n\n1. Any disabling, severe, or unstable medical or psychiatric condition that, in the opinion of the study physician, precludes safe participation in the study or the ability to provide fully informed consent, as assessed by medical and psychiatric history, physical examination, vital signs, and\u002For laboratory tests;\n2. Any severe or unstable co-morbid substance use disorder (e.g., delirium tremens, acute alcohol intoxication) that, in the opinion of the study physician, precludes safe participation in the study;\n3. Currently pregnant or breastfeeding, or planning to become pregnant;\n4. Known or suspected allergy or hypersensitivity to cannabinoids;\n5. History of respiratory disease, severe cardiovascular, cerebrovascular, renal or liver disease;\n6. Current or historic cannabis use disorder;\n7. Taking warfarin, clopidogrel, clobazam, theophylline, clozapine and olanzapine medications as they may interact with cannabinoids in a clinically significant manner if they cannot be switched to a different medication;\n8. Any personal or family history (first degree relative) of primary psychotic disorders (i.e., schizophrenia, schizoaffective disorder) as per DSM-5 criteria;\n9. Unable to abstain from driving any vehicle or operating machinery for at least 10 hours after taking the study medication. In cases where impairment persists beyond the initial 10-hour period, participants must continue to adhere to these restrictions until the impairment resolves;\n10. Actively participating in other interventional clinical trial(s);\n11. Incarcerated, pending legal action or other reasons that might prevent completion of the study.",{"count":526,"type":23},24,[219],"This pilot study will evaluate the feasibility and safety of using 1:1 tetrahydrocannabinol (THC):Cannabidiol (CBD) cannabis oil as an adjunct therapy to methadone-based Opioid Agonist Therapy (OAT) for individuals with opioid use disorder (OUD) in a community setting.",[530,531,29,532],"Opioid Use Disorder","Methadone","Fentanyl",[534,530,29,535,536,537,538,539],"addiction","Harm Reduction","Opioid","Pain","Quality of Life","Cannabidiol","2025-02-14",{"date":542,"type":67},"2025-02-17",{"date":544,"type":67},"2024-05-23",{"date":365,"type":23},{"name":547,"class":74},"BC Centre on Substance Use",{"id":549,"slug":550,"hasResults":11,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":17,"sex":18,"minAge":109,"maxAge":555,"enrollmentInfo":556,"targetDuration":4,"studyType":24,"phases":558,"briefSummary":559,"conditions":560,"keywords":563,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":75},"100469217","phase-2-cannabis-impact-on-alcohol-consumption-100469217","NCT05389930","Cannabis' Impact on Alcohol Consumption","Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods","Inclusion Criteria:\n\n* Age 21 to 50\n* English-speaking\n* cannabis smoking in past two months\n* heavy drinking in past two months\n* in good physical health and weighing \\\u003C 250 lbs\n* zero breath alcohol at each visit\n\nExclusion Criteria:\n\n* positive pregnancy test\n* nursing\n* positive urine toxicology screen for drugs other than cannabis\n* interest to quit or receive treatment for cannabis or alcohol use","50 Years",{"count":557,"type":23},350,[219],"This study employs a repeated measures experimental design to examine the effect of THC-dominant dose of cannabis and CBD-dominant dose of cannabis, relative to placebo, on subsequent drinking in an alcohol choice task in which participants choose either to drink or receive monetary reinforcement for drinks not consumed. Cannabis will be administered simultaneously with an alcohol-priming dose or alcohol placebo.\n\nThe study will enroll up to 350 nontreatment-seeking heavy episodic alcohol drinkers who use cannabis weekly.",[561,404,29,562],"Alcohol Drinking","Alcohol Use Disorder",[564,31,38,534,226,565,566],"alcohol","tetrahydrocannabinol","cannabidiol","2024-08-05",{"date":569,"type":67},"2024-08-06",{"date":571,"type":67},"2023-03-16",{"date":573,"type":23},"2027-03-31",{"name":575,"class":74},"Brown University",{"id":577,"slug":578,"hasResults":11,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":24,"phases":585,"briefSummary":586,"conditions":587,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":75},"100555926","phase-2-a-pilot-study-on-the-effect-of-cannabis-oil-in-untreatable-liver-cancer-patients-100555926","NCT06518434","A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients","A Phase 2a Study on the Anti-tumoral Effect of Cannabis Oil (THC 10% \u002F CBD 5%) in Patients With Advanced Untreatable Hepatocellular Carcinoma","CanHep","Inclusion Criteria:\n\n* Age =\\>18 yrs\n* Histologically proven hepatocellular carcinoma\n* Non-cirrhosis or Child Pugh A cirrhosis\n* Hepatic encephalopathy grade 0 or 1\n* Multidisciplinary treatment (MDT)-advised best supportive care for untreatable advanced HCC or patients unable to undergo or declining treatment for advanced HCC.\n* Minimal life expectancy of 3 months\n* Willing and able to attend follow-up examinations\n* Willing to stop active traffic participation or controlling machinery during the study period if applicable\n* Signed informed consent\n* Language: Dutch or English\n\nExclusion Criteria:\n\n* Child Pugh B or C cirrhosis\n* Hepatic encephalopathy grade 2 or more\n* Previous systemic treatment for HCC\n* Mental conditions rendering the subject incapable to understand the nature, scope and consequences of the trial\n* Use of medicinal cannabis for other purposes\n* Contra-indications for medicinal cannabis oil:\n\n  * Patients who have experienced a myocardial infarction or clinically significant cardiac dysfunction within the last 12 months or have had a cardiac disorder that, in the opinion of the investigator would have put the participant at risk of a clinically significant arrhythmia or myocardial infarction.\n  * Patients with known psychotic disorders\n  * Female patients who are pregnant or lactating\n  * Patients (men or women) intending to start a family\n  * Hypersensitivity to cannabinoids or any of the excipients of the cannabis oil",{"count":189,"type":23},[219],"to study the anti-tumor effect of cannabis oil (THC10% \u002F CBD5%) in untreatable HCC patients based on mRECIST and RECIST criteria",[588,29],"Hepatocellular Carcinoma","2024-07-23",{"date":591,"type":67},"2024-07-24",{"date":593,"type":67},"2021-04-15",{"date":595,"type":23},"2027-04-15",{"name":597,"class":74},"University Medical Center Groningen"]